Shutterstock
Lonza has had a busy opening to 2024, most notably the company announced that it has had a $1.2b offer accepted by Roche Pharmaceuticals to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California. This acquisition aims to significantly increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian contract manufacturing from customers with existing commercial products, and molecules currently on the path to commercialisation within the Lonza network.